In the last trading session, 1.58 million Mineralys Therapeutics Inc (NASDAQ:MLYS) shares changed hands as the company’s beta touched -0.13. With the company’s per share price at $12.40 changed hands at -$1.13 or -8.35% during last session, the market valuation stood at $778.53M. MLYS’s last price was a discount, traded about -48.23% off its 52-week high of $18.38. The share price had its 52-week low at $8.24, which suggests the last value was 33.55% up since then. When we look at Mineralys Therapeutics Inc’s average trading volume, we note the 10-day average is 1.51 million shares, with the 3-month average coming to 977.74K.
Analysts gave the Mineralys Therapeutics Inc (MLYS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended MLYS as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Mineralys Therapeutics Inc’s EPS for the current quarter is expected to be -0.98.
Mineralys Therapeutics Inc (NASDAQ:MLYS) trade information
Instantly MLYS was in red as seen at the end of in last trading. With action -15.42%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 0.73%, with the 5-day performance at -15.42% in the red. However, in the 30-day time frame, Mineralys Therapeutics Inc (NASDAQ:MLYS) is 17.65% up. Looking at the short shares, we see there were 2.22 million shares sold at short interest cover period of 1.38 days.
The consensus price target for the stock as assigned by Wall Street analysts is 30, meaning bulls need an upside of 58.67% from its current market value. According to analyst projections, MLYS’s forecast low is 30 with 30 as the target high. To hit the forecast high, the stock’s price needs a -141.94% plunge from its current level, while the stock would need to soar -141.94% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -170.42%. The 2025 estimates are for Mineralys Therapeutics Inc earnings to decrease by -2.23%, but the outlook for the next 5-year period is at -1.77% per year.
MLYS Dividends
Mineralys Therapeutics Inc is expected to release its next quarterly earnings report on 2025-Feb-11.
Mineralys Therapeutics Inc (NASDAQ:MLYS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.00% of Mineralys Therapeutics Inc shares while 87.07% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 88.85%. There are 87.07% institutions holding the Mineralys Therapeutics Inc stock share, with CATALYS PACIFIC, LLC the top institutional holder. As of 2024-06-30, the company held 18.629% of the shares, roughly 9.19 million MLYS shares worth $107.58 million.
SAMSARA BIOCAPITAL, LLC holds the second largest percentage of outstanding shares, with 10.2822% or 5.07 million shares worth $59.38 million as of 2024-06-30.
